Medicament for treating a manifested lyme disease

US6761891B1 · kind B1 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Markus Simon · Buckenhof, DE
• Weimin Zhong · New York, US
• Reinhard Wallich · Heidelberg, DE
• Michael Kramer · Freiberg, DE

Key dates

• Filing date: Jul 6, 2000
• Grant date: Jul 13, 2004
• Expiry date: Jul 6, 2020

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition for treating Lyme disease contains an antibody as an active agent which is specific for the 24 kDa antigen (OspC) of B. burgdorferi, preferably an antibody which is specific for the 24 kDa antigen (OspC) of B. burgdorferi having the sequence shown in SEQ ID NO.2.